Patents by Inventor Ana Maria Escribano

Ana Maria Escribano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DGAT2 inhibitors
    Patent number: 10053429
    Abstract: The present invention provides compounds of the Formula below: [Formula should be inserted here] Where A, X, R. and R2-R3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: August 21, 2018
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Escribano, Maria Rosario Gonzalez, Celia Lafuente Blanco, Maria Dolores Martin-Ortega Finger, Michael R Wiley
  • NOVEL DGAT2 INHIBITORS
    Publication number: 20180162825
    Abstract: The present invention provides compounds of the Formula below: [Formula should be inserted here] Where A, X, R, and R2-R3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds.
    Type: Application
    Filed: May 19, 2016
    Publication date: June 14, 2018
    Applicant: Eli Lily and Company
    Inventors: Ana Maria Escribano, Maria Rosario Gonzalez, Celia Lafuente Blanco, Maria Dolores Martin-Ortega Finger, Michael R Wiley
  • Aldosterone synthase inhibitor
    Patent number: 8778984
    Abstract: The present invention provides aldosterone synthase inhibitors of the formula: intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: July 15, 2014
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Paul J. Hoogestraat, Thomas Edward Mabry, Quanrong Shen, Ana Maria Escribano
  • Aldosterone Synthase Inhibitor
    Publication number: 20120322841
    Abstract: The present invention provides aldosterone synthase inhibitors of the formula: intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.
    Type: Application
    Filed: June 7, 2012
    Publication date: December 20, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Michael Gregory Bell, Paul J. Hoogestraat, Thomas Edward Mabry, Quanrong Shen, Ana Maria Escribano
  • Compounds and Methods for Treating Dyslipidemia
    Publication number: 20100204207
    Abstract: Compounds of Formula (I): wherein n, m, p, q, Y, R1, R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Application
    Filed: April 20, 2010
    Publication date: August 12, 2010
    Inventors: Xinchao Chen, Christopher Lawrence Cioffi, Sean Richard Dinn, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Saravanan Parthasarathy, Xiaodong Wang
  • Compounds and methods for treating dislipidemia
    Patent number: 7749992
    Abstract: Compounds of formula I wherein n, m, p, q, y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: July 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Douglas Linn Gernert, Christopher Lawrence Cioffi, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • Thiophene and furan compounds
    Patent number: 7642361
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: January 5, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano, Maria Carmen Fernandez, William Joseph Hornback, Alma Maria Jimenez-Aguado, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Compounds and methods for treating dyslipidemia
    Patent number: 7470705
    Abstract: The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: December 30, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Peter Ambrose Lander, Nathan Bryan Mantlo, Eva Maria Martin de la Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • Compounds and Methods for Treating Dyslipidemia
    Publication number: 20080269284
    Abstract: Compounds of Formula I wherein n, q, Y, R1, R2a, R2b, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Application
    Filed: June 22, 2005
    Publication date: October 30, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Maria Escribano, Maria Carmen Fernandez, Nathan Bryan Mantlo, Ana Isabel Mateo-Herranz, Eva Maria Martin De La Nava, Xiaodong Wang
  • Excitatory amino acid receptor antagonists
    Patent number: 7205313
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Excitatory amino acid receptor antagonists
    Patent number: 6924294
    Abstract: The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: August 2, 2005
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano
  • Excitatory amino acid receptor antagonists
    Publication number: 20040138254
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Application
    Filed: December 1, 2003
    Publication date: July 15, 2004
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Mark Alan Winter, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Excitatory amino acid receptor antagonists
    Publication number: 20040053961
    Abstract: The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.
    Type: Application
    Filed: June 12, 2003
    Publication date: March 18, 2004
    Inventors: Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez Manzanares, Ana Maria Escribano
  • Sulphonamide derivatives
    Patent number: 6362230
    Abstract: The present invention provides novel sulphonamide derivatives which are useful for potentiating glutamate receptor function in a mammal requiring treatment, processes for their preparation, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: March 26, 2002
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Dennis Michael Zimmerman, Ana Maria Escribano
  • Heterocyclic sulphonamide derivatives
    Patent number: 6355655
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain heterocyclic sulphonamide derivatives. It also relates to novel heterocyclic sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: March 12, 2002
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Escribano, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulphonamide derivatives
    Patent number: 6174922
    Abstract: The present invention provides novel sulphonamide derivatives which are useful for potentiating glutamate receptor function in a mammal requiring treatment, processes for their preparation, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: January 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Dennis Michael Zimmerman, Ana Maria Escribano